#United States #Atopic Dermatitis #Watertown #Triveni Bio #TRIV-573

Triveni Bio Raises $65 Million Series C Financing

Triveni Bio Inc., an innovative biotechnology firm focused on developing novel antibody therapies for autoimmune and inflammatory disorders, has successfully raised a staggering $65 million in its Series C financing round. This fundraising is pivotal for the company's continued advancement in clinical studies for its first-in-class bispecific compound, TRIV-573, aimed at treating atopic dermatitis among other conditions.

Funding Details and Implications

The Series C round was prominently supported by a reputable syndicate of investors including co-leaders Ascenta Capital and Janus Henderson Investors, alongside significant contributions from Deep Track Capital and existing investors. This considerable influx of capital will enable Triveni to broaden its clinical development scope, particularly by conducting a Phase 2 proof-of-concept trial for TRIV-573 in patients with atopic dermatitis later this year.

TRIV-573 stands out as a next-generation therapy designed with a longer half-life, offering dual inhibition of KLK5/7, which has been identified as critical factors in skin barrier dysfunction, and the Th2 cytokine IL-13. This strategic targeting represents a substantial shift in the treatment paradigm for patients suffering from atopic dermatitis, a condition often resulting in debilitating skin issues and negatively impacting quality of life.

Dr. Vishal Patel, CEO of Triveni Bio, emphasized the importance of this funding, stating, "This financing enables us to disrupt the status quo in atopic dermatitis, addressing not just inflammation, but the underlying dysfunction of the skin barrier, positioning Triveni to bring a long-overdue option to a population of patients still in need of relief."

Advancing Clinical Frontiers

The necessity for innovative solutions in atopic dermatitis has never been greater, especially given the limitations of current standard-of-care treatments. The raise comes at a crucial time following the initiation of first-in-human clinical studies with TRIV-573, highlighting the rapid progression and execution capabilities of the Triveni team.

In conjunction with the Series C round, Evan Rachlin, M.D., Co-Founder, and Managing Partner at Ascenta Capital, will join Triveni’s Board of Directors, further strengthening the company’s governance and strategic direction. Dr. Rachlin remarked, "Triveni Bio has rapidly and efficiently advanced novel programs to address significant gaps in the existing standard-of-care. The speed with which the team has progressed two assets into the clinic—less than one year apart—is a testament to their operational execution."

Recognition and Leadership

The momentum built through this financing aligns with recent accolades for Triveni’s leadership. Dr. Vishal Patel has been recognized as a finalist for the Ernst & Young (EY) Entrepreneur Of The Year® 2026 award, underscoring his impactful leadership in steering innovative programs from conception to clinical trials with impressive speed and rigor.

Understanding TRIV-509 and TRIV-573

Triveni’s lead program, TRIV-509, targets moderate-to-severe atopic dermatitis as a half-life extended monoclonal antibody. With its mechanism of action focusing on the inhibition of proteases, TRIV-509 can significantly influence vital aspects of the condition, such as barrier dysfunction, inflammation, and itching. Currently, TRIV-509 is in a Phase 2 proof-of-concept trial, with data expected by the end of 2026.

On the other hand, TRIV-573 promises to enhance treatment for atopic dermatitis through its potent anti-IL-13 mechanism, which will be validated in the upcoming proof-of-concept trial scheduled to begin soon.

About Triveni Bio

Triveni Bio operates at the forefront of biotechnology, dedicated to advancing antibody therapies for immunological and inflammatory disorders. The company employs a genetics-informed precision medicine approach, aiming to establish proof-of-concept early in the drug development process through continuous insights into genetic and mechanistic biology.

For additional information about Triveni Bio and its innovative research, visit www.triveni.bio.